# Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

> **NCT06935136** · NA · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 60 (estimated)

## Conditions studied

- CAR-T Cell Therapy
- High-risk Large B-cell Lymphoma (LBCL)

## Interventions

- **DRUG:** Axicabtagene Ciloleucel

## Key facts

- **NCT ID:** NCT06935136
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2026-10-09
- **Final completion:** 2028-04-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06935136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06935136, "Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06935136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*